ASMI PPI as­sur­ance

Pharmacy Daily - - FRONT PAGE -

THE Aus­tralian Self-Med­i­ca­tion In­dus­try says con­sumers can have con­fi­dence in the safety pro­file and ef­fec­tive­ness of OTC pro­ton pump in­hibitors (PPIs) when they are used as di­rected.

The or­gan­i­sa­tion was re­spond­ing to re­cent me­dia reports about a study pub­lished in t where re­searchers linked the long-term use of PPIs with a higher risk of dou­bling stom­ach can­cer.

The study was con­ducted on peo­ple treated for Heli­cobac­ter py­lori in­fac­tion, and ASMI said while it pro­vides a “thought­ful anal­y­sis of the ef­fect of lori erad­i­ca­tion... th­ese find­ings and rel­a­tive risks can­not be ex­trap­o­lated to peo­ple who have fre­quent heart­burn or gas­trooe­sophageal re­flux dis­ease (GORD) and for whom a short course of OTC PPIs for symp­tom re­lief may be ap­pro­pri­ate”.

Newspapers in English

Newspapers from Australia

© PressReader. All rights reserved.